Brief: Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
08/07/2024 13:55
July 8 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA ANNOUNCES EXCLUSIVE, GLOBAL LICENSE FOR LEAD
CANDIDATE SPC-15 TARGETING PTSD AND STRESS-INDUCED ANXIETY
DISORDERS
* SILO PHARMA: AGREEMENT WITH COLUMBIA UNIVERSITY TO FURTHER
DEVELOP, MANUFACTURE, COMMERCIALIZE SPC-15
Source text for Eikon: ID:nGNX39QdWt
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement